Myriad Genetics Stock Performance
| MYGN Stock | USD 12.73 0.20 1.55% |
The company secures a Beta (Market Risk) of 0.5, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, Myriad Genetics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Myriad Genetics is expected to be smaller as well. At this point, Myriad Genetics has a negative expected return of -0.48%. Please make sure to verify Myriad Genetics' total risk alpha, kurtosis, as well as the relationship between the Kurtosis and day typical price , to decide if Myriad Genetics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Myriad Genetics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of inconsistent performance in the last few months, the Stock's technical and fundamental indicators remain very healthy which may send shares a bit higher in March 2025. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
Actual Historical Performance (%)
One Day Return (1.55) | Five Day Return (0.47) | Year To Date Return (5.70) | Ten Year Return (61.33) | All Time Return 136.62 |
Last Split Factor 2:1 | Last Split Date 2009-03-26 |
1 | Leerink Partners downgrades Myriad stock to Market Perform, cuts 2025 growth estimate | 12/09/2024 |
2 | Myriad Genetics Inc Unveils Study Highlighting RiskScores Superior Accuracy in ... | 12/19/2024 |
3 | Disposition of 417 shares by Dale Muzzey of Myriad Genetics at 13.71 subject to Rule 16b-3 | 12/31/2024 |
4 | Myriad Genetics Inc Partners with Hannah Storm to Promote Breast Cancer Risk Awareness | 01/10/2025 |
5 | Myriad Genetics Inc Stock Price Down 6.43 percent on Jan 16 | 01/16/2025 |
6 | New study highlights effectiveness and cost benefits of Myriad in lower limb salvage surgeries. | 01/17/2025 |
7 | Myriad Genetics Announces Hereditary Cancer Risk Assessment Program Study Published in ... | 01/21/2025 |
8 | Myriad Genetics Inc Launches Educational Website on Prenatal Genetic Testing | 01/23/2025 |
9 | Why Is Larry Robbins Bullish on Myriad Genetics, Inc. Now - Yahoo Finance | 01/24/2025 |
10 | Myriad Uranium Announces Resignation of Director | 01/28/2025 |
11 | Myriad Genetics Unveils Groundbreaking Eight Weeks Gestation NIPT Study Results at Society for ... | 01/29/2025 |
12 | Quantum Myriad supports 122.9 TB SSDs and in-place system scaling | 01/30/2025 |
13 | Myriad Genetics Announces Two New Patents Granted for its Molecular Residual Disease Assay | 02/05/2025 |
14 | Myriad Genetics Inc Expands Access to Hereditary Cancer Testing Through New Partnership | 02/06/2025 |
| Begin Period Cash Flow | 66.4 M |
Myriad |
Myriad Genetics Relative Risk vs. Return Landscape
If you would invest 1,731 in Myriad Genetics on November 9, 2024 and sell it today you would lose (458.00) from holding Myriad Genetics or give up 26.46% of portfolio value over 90 days. Myriad Genetics is currently does not generate positive expected returns and assumes 2.645% risk (volatility on return distribution) over the 90 days horizon. In different words, 23% of stocks are less volatile than Myriad, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Myriad Genetics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Myriad Genetics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Myriad Genetics, and traders can use it to determine the average amount a Myriad Genetics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1833
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | MYGN |
Estimated Market Risk
| 2.65 actual daily | 23 77% of assets are more volatile |
Expected Return
| -0.48 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.18 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Myriad Genetics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Myriad Genetics by adding Myriad Genetics to a well-diversified portfolio.
Myriad Genetics Fundamentals Growth
Myriad Stock prices reflect investors' perceptions of the future prospects and financial health of Myriad Genetics, and Myriad Genetics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Myriad Stock performance.
| Return On Equity | -0.16 | ||||
| Return On Asset | -0.0535 | ||||
| Profit Margin | (0.14) % | ||||
| Operating Margin | (0.08) % | ||||
| Current Valuation | 1.22 B | ||||
| Shares Outstanding | 91.04 M | ||||
| Price To Earning | 31.95 X | ||||
| Price To Book | 1.61 X | ||||
| Price To Sales | 1.41 X | ||||
| Revenue | 753.2 M | ||||
| Gross Profit | 569.5 M | ||||
| EBITDA | (186.1 M) | ||||
| Net Income | (263.3 M) | ||||
| Cash And Equivalents | 205.1 M | ||||
| Cash Per Share | 2.54 X | ||||
| Total Debt | 152.1 M | ||||
| Debt To Equity | 0.11 % | ||||
| Current Ratio | 3.07 X | ||||
| Book Value Per Share | 8.04 X | ||||
| Cash Flow From Operations | (110.9 M) | ||||
| Earnings Per Share | (1.28) X | ||||
| Market Capitalization | 1.16 B | ||||
| Total Asset | 1.15 B | ||||
| Retained Earnings | (629.5 M) | ||||
| Working Capital | 157.7 M | ||||
| Current Asset | 314.5 M | ||||
| Current Liabilities | 72.3 M | ||||
About Myriad Genetics Performance
By examining Myriad Genetics' fundamental ratios, stakeholders can obtain critical insights into Myriad Genetics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Myriad Genetics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 30.60 | 32.13 | |
| Return On Tangible Assets | (0.47) | (0.44) | |
| Return On Capital Employed | (0.23) | (0.22) | |
| Return On Assets | (0.21) | (0.20) | |
| Return On Equity | (0.30) | (0.29) |
Things to note about Myriad Genetics performance evaluation
Checking the ongoing alerts about Myriad Genetics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Myriad Genetics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Myriad Genetics generated a negative expected return over the last 90 days | |
| The company reported the previous year's revenue of 753.2 M. Net Loss for the year was (263.3 M) with profit before overhead, payroll, taxes, and interest of 569.5 M. | |
| Myriad Genetics currently holds about 205.1 M in cash with (110.9 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.54. | |
| Over 98.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Myriad Genetics Inc Expands Access to Hereditary Cancer Testing Through New Partnership |
- Analyzing Myriad Genetics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Myriad Genetics' stock is overvalued or undervalued compared to its peers.
- Examining Myriad Genetics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Myriad Genetics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Myriad Genetics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Myriad Genetics' stock. These opinions can provide insight into Myriad Genetics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Myriad Genetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Myriad Stock, please use our How to Invest in Myriad Genetics guide.You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Myriad Genetics. If investors know Myriad will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Myriad Genetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.28) | Revenue Per Share | Quarterly Revenue Growth 0.112 | Return On Assets | Return On Equity |
The market value of Myriad Genetics is measured differently than its book value, which is the value of Myriad that is recorded on the company's balance sheet. Investors also form their own opinion of Myriad Genetics' value that differs from its market value or its book value, called intrinsic value, which is Myriad Genetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Myriad Genetics' market value can be influenced by many factors that don't directly affect Myriad Genetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Myriad Genetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Myriad Genetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Myriad Genetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.